The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Generics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Chemotherapy
1.2.3 Biological Targeted Therapy Drugs
1.2.4 Prescription Drugs
1.2.5 Chinese Patent Medicine
1.2.6 Other
1.3 Market by Application
1.3.1 Global Cancer Generics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cancer Generics Market Perspective (2017-2028)
2.2 Cancer Generics Growth Trends by Region
2.2.1 Cancer Generics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Cancer Generics Historic Market Size by Region (2017-2022)
2.2.3 Cancer Generics Forecasted Market Size by Region (2023-2028)
2.3 Cancer Generics Market Dynamics
2.3.1 Cancer Generics Industry Trends
2.3.2 Cancer Generics Market Drivers
2.3.3 Cancer Generics Market Challenges
2.3.4 Cancer Generics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Generics Players by Revenue
3.1.1 Global Top Cancer Generics Players by Revenue (2017-2022)
3.1.2 Global Cancer Generics Revenue Market Share by Players (2017-2022)
3.2 Global Cancer Generics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Generics Revenue
3.4 Global Cancer Generics Market Concentration Ratio
3.4.1 Global Cancer Generics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Generics Revenue in 2021
3.5 Cancer Generics Key Players Head office and Area Served
3.6 Key Players Cancer Generics Product Solution and Service
3.7 Date of Enter into Cancer Generics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Generics Breakdown Data by Type
4.1 Global Cancer Generics Historic Market Size by Type (2017-2022)
4.2 Global Cancer Generics Forecasted Market Size by Type (2023-2028)
5 Cancer Generics Breakdown Data by Application
5.1 Global Cancer Generics Historic Market Size by Application (2017-2022)
5.2 Global Cancer Generics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Cancer Generics Market Size (2017-2028)
6.2 North America Cancer Generics Market Size by Country (2017-2022)
6.3 North America Cancer Generics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Cancer Generics Market Size (2017-2028)
7.2 Europe Cancer Generics Market Size by Country (2017-2022)
7.3 Europe Cancer Generics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Generics Market Size (2017-2028)
8.2 Asia-Pacific Cancer Generics Market Size by Country (2017-2022)
8.3 Asia-Pacific Cancer Generics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Cancer Generics Market Size (2017-2028)
9.2 Latin America Cancer Generics Market Size by Country (2017-2022)
9.3 Latin America Cancer Generics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Generics Market Size (2017-2028)
10.2 Middle East & Africa Cancer Generics Market Size by Country (2017-2022)
10.3 Middle East & Africa Cancer Generics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Teva Pharmaceuticals
11.1.1 Teva Pharmaceuticals Company Detail
11.1.2 Teva Pharmaceuticals Business Overview
11.1.3 Teva Pharmaceuticals Cancer Generics Introduction
11.1.4 Teva Pharmaceuticals Revenue in Cancer Generics Business (2017-2022)
11.1.5 Teva Pharmaceuticals Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Cancer Generics Introduction
11.2.4 Pfizer Revenue in Cancer Generics Business (2017-2022)
11.2.5 Pfizer Recent Development
11.3 Accord Healthcare
11.3.1 Accord Healthcare Company Detail
11.3.2 Accord Healthcare Business Overview
11.3.3 Accord Healthcare Cancer Generics Introduction
11.3.4 Accord Healthcare Revenue in Cancer Generics Business (2017-2022)
11.3.5 Accord Healthcare Recent Development
11.4 Amneal Pharmaceuticals
11.4.1 Amneal Pharmaceuticals Company Detail
11.4.2 Amneal Pharmaceuticals Business Overview
11.4.3 Amneal Pharmaceuticals Cancer Generics Introduction
11.4.4 Amneal Pharmaceuticals Revenue in Cancer Generics Business (2017-2022)
11.4.5 Amneal Pharmaceuticals Recent Development
11.5 Mylan
11.5.1 Mylan Company Detail
11.5.2 Mylan Business Overview
11.5.3 Mylan Cancer Generics Introduction
11.5.4 Mylan Revenue in Cancer Generics Business (2017-2022)
11.5.5 Mylan Recent Development
11.6 DrReddy Laboratories
11.6.1 DrReddy Laboratories Company Detail
11.6.2 DrReddy Laboratories Business Overview
11.6.3 DrReddy Laboratories Cancer Generics Introduction
11.6.4 DrReddy Laboratories Revenue in Cancer Generics Business (2017-2022)
11.6.5 DrReddy Laboratories Recent Development
11.7 Bedford Pharma
11.7.1 Bedford Pharma Company Detail
11.7.2 Bedford Pharma Business Overview
11.7.3 Bedford Pharma Cancer Generics Introduction
11.7.4 Bedford Pharma Revenue in Cancer Generics Business (2017-2022)
11.7.5 Bedford Pharma Recent Development
11.8 Hikma
11.8.1 Hikma Company Detail
11.8.2 Hikma Business Overview
11.8.3 Hikma Cancer Generics Introduction
11.8.4 Hikma Revenue in Cancer Generics Business (2017-2022)
11.8.5 Hikma Recent Development
11.9 Cipla
11.9.1 Cipla Company Detail
11.9.2 Cipla Business Overview
11.9.3 Cipla Cancer Generics Introduction
11.9.4 Cipla Revenue in Cancer Generics Business (2017-2022)
11.9.5 Cipla Recent Development
11.10 Shilpa Medicare
11.10.1 Shilpa Medicare Company Detail
11.10.2 Shilpa Medicare Business Overview
11.10.3 Shilpa Medicare Cancer Generics Introduction
11.10.4 Shilpa Medicare Revenue in Cancer Generics Business (2017-2022)
11.10.5 Shilpa Medicare Recent Development
11.11 Fresenius Kabi
11.11.1 Fresenius Kabi Company Detail
11.11.2 Fresenius Kabi Business Overview
11.11.3 Fresenius Kabi Cancer Generics Introduction
11.11.4 Fresenius Kabi Revenue in Cancer Generics Business (2017-2022)
11.11.5 Fresenius Kabi Recent Development
11.12 Zydus Pharmaceuticals
11.12.1 Zydus Pharmaceuticals Company Detail
11.12.2 Zydus Pharmaceuticals Business Overview
11.12.3 Zydus Pharmaceuticals Cancer Generics Introduction
11.12.4 Zydus Pharmaceuticals Revenue in Cancer Generics Business (2017-2022)
11.12.5 Zydus Pharmaceuticals Recent Development
11.13 Neopharm
11.13.1 Neopharm Company Detail
11.13.2 Neopharm Business Overview
11.13.3 Neopharm Cancer Generics Introduction
11.13.4 Neopharm Revenue in Cancer Generics Business (2017-2022)
11.13.5 Neopharm Recent Development
11.14 Netco
11.14.1 Netco Company Detail
11.14.2 Netco Business Overview
11.14.3 Netco Cancer Generics Introduction
11.14.4 Netco Revenue in Cancer Generics Business (2017-2022)
11.14.5 Netco Recent Development
11.15 Mayne Pharma
11.15.1 Mayne Pharma Company Detail
11.15.2 Mayne Pharma Business Overview
11.15.3 Mayne Pharma Cancer Generics Introduction
11.15.4 Mayne Pharma Revenue in Cancer Generics Business (2017-2022)
11.15.5 Mayne Pharma Recent Development
11.16 Alvogen
11.16.1 Alvogen Company Detail
11.16.2 Alvogen Business Overview
11.16.3 Alvogen Cancer Generics Introduction
11.16.4 Alvogen Revenue in Cancer Generics Business (2017-2022)
11.16.5 Alvogen Recent Development
11.17 Glenmark
11.17.1 Glenmark Company Detail
11.17.2 Glenmark Business Overview
11.17.3 Glenmark Cancer Generics Introduction
11.17.4 Glenmark Revenue in Cancer Generics Business (2017-2022)
11.17.5 Glenmark Recent Development
11.18 HBT Labs
11.18.1 HBT Labs Company Detail
11.18.2 HBT Labs Business Overview
11.18.3 HBT Labs Cancer Generics Introduction
11.18.4 HBT Labs Revenue in Cancer Generics Business (2017-2022)
11.18.5 HBT Labs Recent Development
11.19 Gland
11.19.1 Gland Company Detail
11.19.2 Gland Business Overview
11.19.3 Gland Cancer Generics Introduction
11.19.4 Gland Revenue in Cancer Generics Business (2017-2022)
11.19.5 Gland Recent Development
11.20 Qilu Pharmaceuticals
11.20.1 Qilu Pharmaceuticals Company Detail
11.20.2 Qilu Pharmaceuticals Business Overview
11.20.3 Qilu Pharmaceuticals Cancer Generics Introduction
11.20.4 Qilu Pharmaceuticals Revenue in Cancer Generics Business (2017-2022)
11.20.5 Qilu Pharmaceuticals Recent Development
11.21 Akorn Pharmaceuticals
11.21.1 Akorn Pharmaceuticals Company Detail
11.21.2 Akorn Pharmaceuticals Business Overview
11.21.3 Akorn Pharmaceuticals Cancer Generics Introduction
11.21.4 Akorn Pharmaceuticals Revenue in Cancer Generics Business (2017-2022)
11.21.5 Akorn Pharmaceuticals Recent Development
11.22 MSN Group
11.22.1 MSN Group Company Detail
11.22.2 MSN Group Business Overview
11.22.3 MSN Group Cancer Generics Introduction
11.22.4 MSN Group Revenue in Cancer Generics Business (2017-2022)
11.22.5 MSN Group Recent Development
11.23 Wockhardt
11.23.1 Wockhardt Company Detail
11.23.2 Wockhardt Business Overview
11.23.3 Wockhardt Cancer Generics Introduction
11.23.4 Wockhardt Revenue in Cancer Generics Business (2017-2022)
11.23.5 Wockhardt Recent Development
11.24 Rising Pharma
11.24.1 Rising Pharma Company Detail
11.24.2 Rising Pharma Business Overview
11.24.3 Rising Pharma Cancer Generics Introduction
11.24.4 Rising Pharma Revenue in Cancer Generics Business (2017-2022)
11.24.5 Rising Pharma Recent Development
11.25 Apotex
11.25.1 Apotex Company Detail
11.25.2 Apotex Business Overview
11.25.3 Apotex Cancer Generics Introduction
11.25.4 Apotex Revenue in Cancer Generics Business (2017-2022)
11.25.5 Apotex Recent Development
11.26 Taro Pharmaceuticals
11.26.1 Taro Pharmaceuticals Company Detail
11.26.2 Taro Pharmaceuticals Business Overview
11.26.3 Taro Pharmaceuticals Cancer Generics Introduction
11.26.4 Taro Pharmaceuticals Revenue in Cancer Generics Business (2017-2022)
11.26.5 Taro Pharmaceuticals Recent Development
11.27 Sun Pharma
11.27.1 Sun Pharma Company Detail
11.27.2 Sun Pharma Business Overview
11.27.3 Sun Pharma Cancer Generics Introduction
11.27.4 Sun Pharma Revenue in Cancer Generics Business (2017-2022)
11.27.5 Sun Pharma Recent Development
11.28 Alkem Laboratories
11.28.1 Alkem Laboratories Company Detail
11.28.2 Alkem Laboratories Business Overview
11.28.3 Alkem Laboratories Cancer Generics Introduction
11.28.4 Alkem Laboratories Revenue in Cancer Generics Business (2017-2022)
11.28.5 Alkem Laboratories Recent Development
11.29 Endo Pharma
11.29.1 Endo Pharma Company Detail
11.29.2 Endo Pharma Business Overview
11.29.3 Endo Pharma Cancer Generics Introduction
11.29.4 Endo Pharma Revenue in Cancer Generics Business (2017-2022)
11.29.5 Endo Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Cancer Generics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Biological Targeted Therapy Drugs
Table 4. Key Players of Prescription Drugs
Table 5. Key Players of Chinese Patent Medicine
Table 6. Key Players of Other
Table 7. Global Cancer Generics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Cancer Generics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Cancer Generics Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Cancer Generics Market Share by Region (2017-2022)
Table 11. Global Cancer Generics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Cancer Generics Market Share by Region (2023-2028)
Table 13. Cancer Generics Market Trends
Table 14. Cancer Generics Market Drivers
Table 15. Cancer Generics Market Challenges
Table 16. Cancer Generics Market Restraints
Table 17. Global Cancer Generics Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Cancer Generics Market Share by Players (2017-2022)
Table 19. Global Top Cancer Generics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Generics as of 2021)
Table 20. Ranking of Global Top Cancer Generics Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Cancer Generics Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Cancer Generics Product Solution and Service
Table 24. Date of Enter into Cancer Generics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Cancer Generics Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Cancer Generics Revenue Market Share by Type (2017-2022)
Table 28. Global Cancer Generics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Cancer Generics Revenue Market Share by Type (2023-2028)
Table 30. Global Cancer Generics Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Cancer Generics Revenue Market Share by Application (2017-2022)
Table 32. Global Cancer Generics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Cancer Generics Revenue Market Share by Application (2023-2028)
Table 34. North America Cancer Generics Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Cancer Generics Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Cancer Generics Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Cancer Generics Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Cancer Generics Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Cancer Generics Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Cancer Generics Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Cancer Generics Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Cancer Generics Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Cancer Generics Market Size by Country (2023-2028) & (US$ Million)
Table 44. Teva Pharmaceuticals Company Detail
Table 45. Teva Pharmaceuticals Business Overview
Table 46. Teva Pharmaceuticals Cancer Generics Product
Table 47. Teva Pharmaceuticals Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 48. Teva Pharmaceuticals Recent Development
Table 49. Pfizer Company Detail
Table 50. Pfizer Business Overview
Table 51. Pfizer Cancer Generics Product
Table 52. Pfizer Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 53. Pfizer Recent Development
Table 54. Accord Healthcare Company Detail
Table 55. Accord Healthcare Business Overview
Table 56. Accord Healthcare Cancer Generics Product
Table 57. Accord Healthcare Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 58. Accord Healthcare Recent Development
Table 59. Amneal Pharmaceuticals Company Detail
Table 60. Amneal Pharmaceuticals Business Overview
Table 61. Amneal Pharmaceuticals Cancer Generics Product
Table 62. Amneal Pharmaceuticals Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 63. Amneal Pharmaceuticals Recent Development
Table 64. Mylan Company Detail
Table 65. Mylan Business Overview
Table 66. Mylan Cancer Generics Product
Table 67. Mylan Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 68. Mylan Recent Development
Table 69. DrReddy Laboratories Company Detail
Table 70. DrReddy Laboratories Business Overview
Table 71. DrReddy Laboratories Cancer Generics Product
Table 72. DrReddy Laboratories Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 73. DrReddy Laboratories Recent Development
Table 74. Bedford Pharma Company Detail
Table 75. Bedford Pharma Business Overview
Table 76. Bedford Pharma Cancer Generics Product
Table 77. Bedford Pharma Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 78. Bedford Pharma Recent Development
Table 79. Hikma Company Detail
Table 80. Hikma Business Overview
Table 81. Hikma Cancer Generics Product
Table 82. Hikma Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 83. Hikma Recent Development
Table 84. Cipla Company Detail
Table 85. Cipla Business Overview
Table 86. Cipla Cancer Generics Product
Table 87. Cipla Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 88. Cipla Recent Development
Table 89. Shilpa Medicare Company Detail
Table 90. Shilpa Medicare Business Overview
Table 91. Shilpa Medicare Cancer Generics Product
Table 92. Shilpa Medicare Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 93. Shilpa Medicare Recent Development
Table 94. Fresenius Kabi Company Detail
Table 95. Fresenius Kabi Business Overview
Table 96. Fresenius Kabi Cancer GenericsProduct
Table 97. Fresenius Kabi Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 98. Fresenius Kabi Recent Development
Table 99. Zydus Pharmaceuticals Company Detail
Table 100. Zydus Pharmaceuticals Business Overview
Table 101. Zydus Pharmaceuticals Cancer GenericsProduct
Table 102. Zydus Pharmaceuticals Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 103. Zydus Pharmaceuticals Recent Development
Table 104. Neopharm Company Detail
Table 105. Neopharm Business Overview
Table 106. Neopharm Cancer GenericsProduct
Table 107. Neopharm Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 108. Neopharm Recent Development
Table 109. Netco Company Detail
Table 110. Netco Business Overview
Table 111. Netco Cancer GenericsProduct
Table 112. Netco Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 113. Netco Recent Development
Table 114. Mayne Pharma Company Detail
Table 115. Mayne Pharma Business Overview
Table 116. Mayne Pharma Cancer GenericsProduct
Table 117. Mayne Pharma Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 118. Mayne Pharma Recent Development
Table 119. Alvogen Company Detail
Table 120. Alvogen Business Overview
Table 121. Alvogen Cancer GenericsProduct
Table 122. Alvogen Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 123. Alvogen Recent Development
Table 124. Glenmark Company Detail
Table 125. Glenmark Business Overview
Table 126. Glenmark Cancer GenericsProduct
Table 127. Glenmark Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 128. Glenmark Recent Development
Table 129. HBT Labs Company Detail
Table 130. HBT Labs Business Overview
Table 131. HBT Labs Cancer GenericsProduct
Table 132. HBT Labs Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 133. HBT Labs Recent Development
Table 134. Gland Company Detail
Table 135. Gland Business Overview
Table 136. Gland Cancer GenericsProduct
Table 137. Gland Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 138. Gland Recent Development
Table 139. Qilu Pharmaceuticals Company Detail
Table 140. Qilu Pharmaceuticals Business Overview
Table 141. Qilu Pharmaceuticals Cancer GenericsProduct
Table 142. Qilu Pharmaceuticals Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 143. Qilu Pharmaceuticals Recent Development
Table 144. Akorn Pharmaceuticals Company Detail
Table 145. Akorn Pharmaceuticals Business Overview
Table 146. Akorn Pharmaceuticals Cancer GenericsProduct
Table 147. Akorn Pharmaceuticals Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 148. Akorn Pharmaceuticals Recent Development
Table 149. MSN Group Company Detail
Table 150. MSN Group Business Overview
Table 151. MSN Group Cancer GenericsProduct
Table 152. MSN Group Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 153. MSN Group Recent Development
Table 154. Wockhardt Company Detail
Table 155. Wockhardt Business Overview
Table 156. Wockhardt Cancer GenericsProduct
Table 157. Wockhardt Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 158. Wockhardt Recent Development
Table 159. Rising Pharma Company Detail
Table 160. Rising Pharma Business Overview
Table 161. Rising Pharma Cancer GenericsProduct
Table 162. Rising Pharma Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 163. Rising Pharma Recent Development
Table 164. Apotex Company Detail
Table 165. Apotex Business Overview
Table 166. Apotex Cancer GenericsProduct
Table 167. Apotex Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 168. Apotex Recent Development
Table 169. Taro Pharmaceuticals Company Detail
Table 170. Taro Pharmaceuticals Business Overview
Table 171. Taro Pharmaceuticals Cancer GenericsProduct
Table 172. Taro Pharmaceuticals Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 173. Taro Pharmaceuticals Recent Development
Table 174. Sun Pharma Company Detail
Table 175. Sun Pharma Business Overview
Table 176. Sun Pharma Cancer GenericsProduct
Table 177. Sun Pharma Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 178. Sun Pharma Recent Development
Table 179. Alkem Laboratories Company Detail
Table 180. Alkem Laboratories Business Overview
Table 181. Alkem Laboratories Cancer GenericsProduct
Table 182. Alkem Laboratories Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 183. Alkem Laboratories Recent Development
Table 184. Endo Pharma Company Detail
Table 185. Endo Pharma Business Overview
Table 186. Endo Pharma Cancer GenericsProduct
Table 187. Endo Pharma Revenue in Cancer Generics Business (2017-2022) & (US$ Million)
Table 188. Endo Pharma Recent Development
Table 189. Research Programs/Design for This Report
Table 190. Key Data Information from Secondary Sources
Table 191. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Generics Market Share by Type: 2021 VS 2028
Figure 2. Chemotherapy Features
Figure 3. Biological Targeted Therapy Drugs Features
Figure 4. Prescription Drugs Features
Figure 5. Chinese Patent Medicine Features
Figure 6. Other Features
Figure 7. Global Cancer Generics Market Share by Application in 2021 & 2028
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Drug Center Case Studies
Figure 11. Other Case Studies
Figure 12. Cancer Generics Report Years Considered
Figure 13. Global Cancer Generics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global Cancer Generics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Cancer Generics Market Share by Region: 2021 VS 2028
Figure 16. Global Cancer Generics Market Share by Players in 2021
Figure 17. Global Top Cancer Generics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Generics as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Cancer Generics Revenue in 2021
Figure 19. North America Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. North America Cancer Generics Market Share by Country (2017-2028)
Figure 21. United States Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Cancer Generics Market Share by Country (2017-2028)
Figure 25. Germany Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Cancer Generics Market Share by Region (2017-2028)
Figure 33. China Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Japan Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. South Korea Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Southeast Asia Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. India Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Australia Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Latin America Cancer Generics Market Share by Country (2017-2028)
Figure 41. Mexico Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Brazil Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Middle East & Africa Cancer Generics Market Share by Country (2017-2028)
Figure 45. Turkey Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Saudi Arabia Cancer Generics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Teva Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 48. Pfizer Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 49. Accord Healthcare Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 50. Amneal Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 51. Mylan Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 52. DrReddy Laboratories Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 53. Bedford Pharma Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 54. Hikma Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 55. Cipla Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 56. Shilpa Medicare Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 57. Fresenius Kabi Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 58. Zydus Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 59. Neopharm Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 60. Netco Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 61. Mayne Pharma Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 62. Alvogen Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 63. Glenmark Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 64. HBT Labs Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 65. Gland Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 66. Qilu Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 67. Akorn Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 68. MSN Group Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 69. Wockhardt Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 70. Rising Pharma Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 71. Apotex Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 72. Taro Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 73. Sun Pharma Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 74. Alkem Laboratories Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 75. Endo Pharma Revenue Growth Rate in Cancer Generics Business (2017-2022)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed